logo
‘There is something wrong': Patients say they are paying out of pocket for cataract surgeries at private clinics

‘There is something wrong': Patients say they are paying out of pocket for cataract surgeries at private clinics

It all started at the optometrist.
Stephen Purdey was at a regular checkup to update his prescription last summer when his optometrist flagged something in his eye. The optometrist thought it was cataracts, but recommended Purdey visit an ophthalmologist to confirm.
So Purdey visited a private clinic in Toronto in March for a consultation after months on the wait-list to see a specialist, and that is where he said he started to feel 'vulnerable and susceptible.'
'Because of the combination of wanting to do the best thing for yourself,' said Purdey, who is in his 70s. 'Plus not necessarily understanding everything that the doctors are telling you, you really are as a patient vulnerable to suggestions.'
'And that's what happened to me.'
The ophthalmologist he was referred to, according to Purdey, acknowledged that the patient could get his procedure done for free under OHIP.
Cataract surgery is considered a 'medically necessary surgery' by the province, so even if a person opts to go to a private clinic they shouldn't be billed for the basic OHIP-covered procedure.
Patients who spoke to the Star said they went in for cataract surgery at private clinics and felt they had to pay between a couple of hundred and thousands of dollars out of pocket, whether to bypass reportedly long wait times or receive better treatment, including upgraded lenses.
Their stories come at a time when the provincial government continues to expand the number of privately run surgical and diagnostic centres performing cataract procedures, a move first announced two years ago. They also raise questions about whether there are sufficient guardrails in place to make sure patients don't feel pressured to pay out of pocket for upgrades they may not need.
In Purdey's case, he said his ophthalmologist offered him other options, such as laser-based eye measurements, instead of a free ultrasound measurement, and 'better quality' corrective lenses — treatments that would cost money but, to Purdey, sounded appealing.
'Right away you have the impression that lasers are better than ultrasound,' he said of the measurement procedure. 'And they said, 'Yeah, that's true.''
Laser-based measurements
have been found to be more accurate
than an ultrasound, although
the American Academy of Ophthalmology
notes that there does not appear to be a difference between using a laser or ultrasound during the cataract surgery itself.
Purdey was convinced, however, so he agreed to spend $650 on the laser measurements and an astigmatism test and said he'd consider paying another $200 to $1,600 for the so-called better lenses, then went home.
The four patients who spoke to the Star for this story are older adults who were worried that they might forever damage their vision if they didn't get surgery for their cataracts.
Some of these same patients also said they didn't think they were given all the information they needed to make a decision about whether to pay for so-called better measurements and lenses.
'It is really out of control,' said Natalie Mehra, executive director of the Ontario Health Coalition (OHC), an advocacy group focused on protecting public health care.
'Essentially it's like there isn't public medicare when it comes to eye surgery in Ontario,' says Natalie Mehra, executive director of the Ontario Health Coalition, an advocacy group focused on protecting public health care. 'It's gone.'
Things have gotten so bad from the perspective of the OHC that the group is filing formal complaints with the provincial and federal governments next week, Mehra said.
She said some private clinics around the province bill OHIP for medically necessary cataract surgeries, as they are allowed to, but also charge patients 'mandatory' user fees for things like eye measurements or the surgery itself in a practice known as extra-billing — which is illegal under Ontario law and a breach of the Canada Health Act. Extra-billing also includes charging patients for speedier care.
Mehra noted that the onus to report extra-billing to the province is on patients, many of whom do not realize that such 'mandatory' user fees aren't allowed. After investigating, if the province finds that extra-billing took place, it is required to report this annually to the federal government. Ottawa, in turn, will then claw back a certain amount of funding for the province's medicare program under the Canada Health Act.
And, on top of the extra-billing, private clinics are charging patients add-ons under the guise that they are medically necessary for cataracts, Mehra said.
Last year, Mehra said the coalition received more than 200 complaints over alleged extra-billing for cataract surgeries, one of the top two concerns the group heard from Ontarians. The other was about patients being kicked out of hospital before they are ready to be discharged. And Mehra said she believes there are probably thousands more who just don't know that they're being charged for what should be a free procedure.
For its part, the provincial Ministry of Health said that 32,000 people had publicly funded cataract surgery at community surgical and diagnostic centres in 2024.
'We will continue to deliver more connected, convenient care in every corner of the province, always ensuring that people are accessing the care they need with their OHIP card, never their credit card,' ministry spokesperson Ema Popovic said in an emailed statement.
Still, Mehra said the complaints heard by the OHC run counter to the intentions of the province's medicare system — something patients also echoed in interviews with the Star.
'Essentially it's like there isn't public medicare when it comes to eye surgery in Ontario,' Mehra said. 'It's gone.'
Up until her death in April from complications following cardiac surgery, something about a procedure Judith Deutsch had on her cataract back in 2022
didn't sit right with her, said husband Jim Deutsch.
Judith Deutsch, pictured here in March, didn't 'feel good' about her experience seeking care for her cataracts three years ago up until her death in April, husband Jim said.
Three years earlier, the Toronto couple had decided to go to a private clinic after they were told the wait time for cataract surgery covered by OHIP 'was going to be too long' by a doctor at a separate clinic. They considered the situation to be an 'emergency' — she incurred a concussion and a gash on her face because she couldn't see well — so the couple was willing to pay out of pocket to get care faster.
'It was going to cost a lot of money,' Jim told the Star. 'But she kept falling and just wanted to get it done as quickly as possible.'
Jim said he doesn't believe that he and his wife were scammed — they were aware of the private option and had the means to afford it. But he said the couple still didn't 'feel good' about paying to 'jump the queue' for Judith's surgery.
The OHC's Mehra said that long wait times are commonly mentioned by doctors at private clinics to encourage patients to pay out of pocket for their surgeries.
'They say the wait times in the public hospital are two years, which they are not,' Mehra said. 'Most people are getting it in 90 days, so they lie to patients and convince them to pay.'
According to
the province's surgery wait-time website
at the time of publication, the average wait time between a referral and the first clinician appointment for the lowest priority patients is 100 days. Meanwhile, the average wait time between a clinical decision for a surgery and the operation itself is 103 days.
It's not just wait times; doctors also upsell patients with 'medically unnecessary stuff,' Mehra said. She said the OHC has heard from past cataract patients that they were
encouraged to buy corrective lenses that address non-cataract issues like astigmatism.
Judith was one of these patients, with Jim saying his wife ended up paying more than $5,000 for her surgery, including specialty lenses that she thought were connected to her cataracts and
would lead to better outcomes for her vision, but later learned were for other eye conditions.
Although the couple willingly paid more to get faster care, they say they weren't aware the specialty lenses weren't necessary.
Mehra said she has also heard of patients being charged for post-operative medicine — something Paula from Barrie told the Star separately.
Paula told the Star she had to pay $230 for eye drops after her 2023 surgery at a private clinic, on top of the $5,000 she paid for special lenses and to get faster care. (She said her ophthalmologist told her the wait would be over a year if she did not pay $2,500.)
'That's not right,' Paula said of the eye drop charges. 'They should be covered.'
The Star agreed to use only Paula's first name since she has glaucoma and worries that speaking publicly could interfere with her ability to receive care.
While Paula knew going into her surgery that she wanted to get upgraded lenses and extra measurements, she said the ophthalmologist didn't ask her if she wanted the upgraded measurements.
'They should have asked me,' she said. 'If there were two options, they should have given me the option of 1 or 2.'
Jim Deutsch thinks that his wife's experience seeking care for her cataracts stems from a failure of Canada's medicare program.
The office of Ontario's Patient Ombudsman received some 4,429 complaints in the 2023-24 fiscal year — the most since it opened in 2016.
The office of Ontario's Patient Ombudsman received some 4,429 complaints in the 2023-24 fiscal year — the most since it opened in 2016.
'Medicare ended up being something that was quite different from what (Tommy Douglas) originally imagined,' said Deutsch, a psychiatrist who moved to Canada from the U.S. decades ago to work in the country's public system.
'Along the way we've ended up with this situation of scarcity and profit and allowing there to be private clinics that will offer something more speedily.'
Paula, too, believes the current system isn't fair — even if she said she would pay out of pocket again to get her surgery done faster.
'There is something wrong with the whole system,' she said, describing it as 'two-tier medicine.'
The OHC pins the blame on the Ford government, specifically the passage of Bill 60: Your Health Act in 2023.
The legislation
allows more private clinics to provide certain publicly funded procedures
, including cataract surgery. The provincial government said the Act was intended to reduce long wait times, while critics, including the OHC, said it would draw resources away from public hospitals.
'No one is able to regulate and control the private market for health care,' Mehra said. 'The most sensible thing we can do is bring (cataract surgeries) back into public hospitals.'
The Ministry of Health's Popovic stood by Bill 60 in her statement to the Star.
'To be very clear, Ontario has provisions through legislation that prohibit a patient from being charged for an OHIP-covered service, legislation that was strengthened by our government through Bill 60,' she said.
Popovic added that anyone who believes they have been charged for an OHIP-covered service can contact the Commitment to the Future of Medicare Act program to ask for a review, and that those who have been found to have been billed will be reimbursed.
After coming home from the private eye clinic, Purdey changed his mind; he wasn't going to pay for the laser measurements or other add-ons.
'I was told that the laser measurement stuff was better,' he said, 'but they didn't really tell me how much better it was.'
He called up the clinic to ask for the OHIP-funded procedures and in late May he had the first round of publicly funded surgery on one of his eyes.
'I'm quite satisfied,' Purdey said the day after his surgery. 'I feel like I narrowly missed getting trapped into spending a whole lot of money.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says
Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says

CBS News

time2 days ago

  • CBS News

Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says

There's a new medical issue on Martha's Vineyard, and it's impacting the way people eat. It's known as "alpha-gal syndrome," and is not a tick-borne illness, but rather an allergy in response to a tick bite. "It's skyrocketing across the island," explained Patrick Roden-Reynolds, a biologist and tick researcher on Martha's Vineyard. The allergy can come in response to a bite from a Lone Star tick, which are common in the south but have recently shown up in large numbers on the Vineyard - due to a combination of climate and an unusually large deer population, experts say. "In the last 15 years, the Lone Star tick has gone from non-existent on the island to fully abundant and everywhere," Roden-Reynolds explained. "So, the way I've been explaining it, our public health burden with just deer ticks and Lyme disease was, you know, already here at our eyeballs, and now with the Lone Star tick and alpha-gal concerns, it's way above our head." The allergy can cause a range of symptoms up to serious anaphylaxis in response to eating or even being near mammal meat, dairy, and some mammal-related products inside medicine. "Alpha-gal syndrome has been so explosive on Martha's Vineyard that pretty much it comes up in every conversation that I have, ticks or alpha-gal syndrome, even without folks knowing what I do for work," explained Lea Hamner, an epidemiologist on the island. Hamner provided WBZ with a graph that shows the increase in positive allergy testing on the island - from 32 in 2021 to more than 500 positive tests in 2024. There is still a lot to learn about the allergy, Hamner says, though one thing is known: people can go into remission, and an exacerbating force that makes the allergy worse is an increase in tick bites. "One thing that does influence whether you have a shot at remission is whether you stop getting tick bites," Hamner said. "More tick bites can send you back into allergy or keep you there. And so that's one of the really key things, is preventing more tick bites." How to prevent tick bites? According to experts: The prevalence of the allergy has changed the way restaurants are doing business. "Restaurants, food trucks, and other food establishments are including alpha-gal-friendly menu items on their menu," Roden-Reynolds explained. "Alpha-gal is now a selection you can choose on your list of allergies if you're ordering takeout, too."

Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work
Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work

Business Wire

time4 days ago

  • Business Wire

Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work

AUSTIN, Texas--(BUSINESS WIRE)-- Alen, a leader in the air purification industry, today celebrates 20 years of creating best-in-class air purifiers that ensure the health and safety for millions of Americans. The Austin-based company has become a trusted name in clean air solutions since its founding in 2005, recognized by leading industry and scientific experts for its powerful technology, thoughtful design and its deep commitment to healthier living. 'Alen began with one goal in mind. Make clean air simple, effective, and accessible, for people and pets,' said Warburg Lee, Founder and CEO of Alen. 'Since then, both outdoor and indoor air quality have worsened due to wildfires, increased allergens, and viruses, making our mission even more critical. We're a health and wellness company, not just an air purifier company, with a mandate to create healthy living and working environments. From our earliest models to our most recent advanced purifier models, our north star is that we remove 99.9 percent of airborne particulates while operating quietly in the background to protect what matters most.' 20 years of achievements include: Growing from start-up to nationally recognized brand with over 50 team members, availability in all 50 states, serving more than 2 million customers worldwide, and developing the fifth generation of advanced air purifier systems with new products launching in October 2025. Meeting critical third-party standards, including certifications from ENERGY STAR, Quiet Mark, SleepScore Labs, and the Asthma and Allergy Friendly Program. Products are tested to remove up to 99.9 percent of airborne particles down to 0.1 microns. Sought-after by national retailers including Lowe's and Amazon to carry Alen products because they are a trusted brand for homes, schools, and businesses across the country. Continued excellence in technology, developing proprietary technology, industry-first features, and responsive design with intelligent sensors and proprietary airID technology that detects and responds to real-time air quality changes, automatically adjusting to remove pollutants like dust, smoke, and chemicals for cleaner, healthier air. Day-one pursuit of design to fit the aesthetics of modern living. Alen purifiers blend seamlessly into bedrooms, offices, classrooms, and large commercial spaces with multiple sizes, ultra-quiet performance, and customizable designer panels. Alen's mission to improve indoor air became a national movement for wellness. Alen continues to lead with purpose, innovation, and a long-standing commitment to help people breathe better and live healthier. Alen is preparing to introduce new models later this year, building on its reputation for premium air purification and breakthrough technology. These upcoming releases will reinforce its position as a leader in clean air solutions. Alen is poised to deliver greater impact across both retail and business-to-business markets, backed by ongoing innovation, supply chain strength, and strategic commercial partnerships. To explore Alen's full range of air purification solutions, visit About Alen Alen is an Austin-based innovator of high-performance air purifiers, committed to creating healthier indoor environments through advanced, scientifically validated technology. Alen's purifiers use True HEPA filters and are independently certified by Quiet Mark, the Asthma & Allergy Friendly® Certification Program, SleepScore Labs, and ENERGY STAR® for delivering best-in-class air purification, energy efficiency, ultra-quiet operation, and improved sleep quality. Alen's mission to enhance quality of life in homes, workplaces, and shared spaces is driven by the belief that wellness begins with pure air. Alen empowers individuals and families to lead healthier lives with cleaner, safer air and greater peace of mind through proprietary features like airID smart sensor technology and a commitment to lifetime reliability.

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Business Wire

time5 days ago

  • Business Wire

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and South Africa' said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "We are encouraged by the strong enthusiasm from patients and physicians, including at the recent HAEA conference, where we had the opportunity to engage with the HAE community. We were also thrilled to announce a strategic partnership with Kaken. Their expertise supports our ongoing Phase 3 enrollment, contributes to strengthening our financial position, and may ultimately help expand global patient access to navenibart.' Navenibart (STAR-0215) In August, Astria announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical for navenibart. Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for an additional $16 million in total commercialization and sales milestones. In addition to these payments, Astria is also eligible for tiered royalties with the royalty rate as a percentage of net sales up to 30%, and partial Phase 3 cost reimbursement. The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, which are designed to support registration globally. ALPHA-ORBIT is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of navenibart over a 6-month treatment period, with dosing arms every 3 months (Q3M) and every 6 months (Q6M). Enrollment is ongoing and top-line results are expected in early 2027. After completing ALPHA-ORBIT, eligible patients may continue into the open-label ORBIT-EXPANSE study, which includes 6 months of additional treatment followed by a patient-centric flexible dosing phase. Positive initial results from the ongoing ALPHA-SOLAR long-term open-label trial of navenibart were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. All 16 ALPHA-STAR target enrollment participants continued into ALPHA-SOLAR and the results are highly consistent with ALPHA-STAR - showing robust overall reduction in monthly attack rates (92% mean and 97% median) and a well-tolerated safety profile. STAR-0310 Astria is developing STAR-0310, an investigational high-potency and long-acting monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD) and potentially other indications. STAR-0310 was intentionally designed to capitalize on the learnings of OX40 receptor and OX40 ligand programs with the goal of having the best overall OX40 therapy. The Company initiated a Phase 1a clinical trial of STAR-0310 in healthy subjects in January 2025. The Phase 1a trial is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants, with early proof-of-concept (POC) results expected in the third quarter of 2025. Data presented at the European Academy of Allergy and Clinical Immunology (EAACI) annual congress support STAR-0310 as a potential best-in-class OX40 antagonist, with a unique allosteric inhibition mechanism, enhanced disruption of OX40/OX40L signaling compared to other agents, and pure antagonistic activity without agonism. These findings, along with previously reported low ADCC activity and robust cytokine suppression, highlight STAR-0310's differentiated profile and its potential to achieve deeper inhibition of T cell responses. Upcoming Corporate Events Cantor Global Healthcare Conference (September 3-5, 2025, New York, New York) Second Quarter 2025 Financial Results Cash Position: As of June 30, 2025, Astria had cash, cash equivalents and short-term investments of $259.2 million, compared to $328.1 million as of December 31, 2024. The Company expects that its cash, cash equivalents and short-term investments as of June 30, 2025, together with the Kaken upfront payment and expected reimbursement of a portion of the Company's Phase 3 program costs, will be sufficient to fund its current operating plan into 2028, including (i) for navenibart, support for all program activities through completion of our ALPHA-ORBIT Phase 3 trial, including activities related to the planned ORBIT-EXPANSE long-term trial and Phase 3 development and testing of drug device combinations, and (ii) for STAR-0310, the completion of the ongoing Phase 1a clinical trial of healthy subjects. Net cash used in operating activities for the three months ended June 30, 2025 was $36.1 million, compared to $16.8 million for the three months ended June 30, 2024. R&D Expenses: Research and development expenses were $25.9 million for the three months ended June 30, 2025, compared to $20.7 million for the three months ended June 30, 2024. The increase in research and development expenses was attributed to an increase in navenibart expenses related to the support of the ALPHA-ORBIT clinical trial and employee expenses, partially due to increases in stock-based compensation and company growth to support the advancement of our programs, during the three months ended June 30, 2025. G&A Expenses: General and administrative expenses were $9.9 million for the three months ended June 30, 2025, compared to $8.1 million for the three months ended June 30, 2024. The increase in general and administrative expenses was attributable to company growth to support the advancement of our programs, stock-based compensation and other professional services. Operating Loss: Loss from operations was $35.8 million for the three months ended June 30, 2025, compared to $28.8 million for the three months ended June 30, 2024. Net Loss: Net loss was $33.1 million for the three months ended June 30, 2025, compared to a net loss of $24.2 million for the three months ended June 30, 2024. Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was $0.57 for the three months ended June 30, 2025, compared to a net loss basic and diluted of $0.43 per share for the three months ended June 30, 2024. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is an investigational monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing of receipt of topline results from the navenibart ALPHA-ORBIT Phase 3 trial; the goals and objectives of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, including that they are designed to support registration of Q3M and Q6M navenibart administration; our goal of developing two dosing options for navenibart; the potential for navenibart in the HAE market, including the potential to be the market leading treatment in HAE, the potential therapeutic and other benefits of navenibart as a treatment for HAE, and our vision and goals for the program; the objectives, goals and potential payments from our agreement with Kaken Pharmaceutical; the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the nature and timing of receipt of early proof-of-concept results from such trial, including our expectation that such results will inform on STAR-0310's differentiated profile; the potential to develop STAR-0310 in additional indications; our goals and vision for STAR-0310; statements about the Company's current operating plan and the Company's anticipated cash runway; and the goal of bringing life changing therapies to patients and families affected by allergic and immunological diseases and to become a leading allergy and immunology company. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies, including of navenibart and STAR-0310, may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the navenibart Phase 1a clinical trial and the initial results from the ALPHA-STAR trial, may not be replicated in later stage clinical trials, including additional and final results from the ALPHA-STAR trial or the planned navenibart Phase 3 development program; the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the FDA and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates, and devices for such product candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates, and devices for such product candidates, on a cost-effective and timely basis, and to develop dosages and formulation for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefore; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310, and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks with respect to the ability of STAR-0310 to compete in AD and the anticipated position and attributes of STAR-0310 in AD based on its preclinical profile; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities, including the costs associated with commercialization of navenibart if regulatory approval is obtained, and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' sections of our Annual Report on Form 10-K for the period ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof. Astria Therapeutics, Inc. C onsolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) Astria Therapeutics, Inc. Selected Consolidated Balance Sheets Data (In thousands) (Unaudited) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 76,319 $ 59,820 Short-term investments 182,859 268,312 Right-of-use asset 4,546 5,114 Other current and long-term assets 18,200 9,117 Total assets 281,924 342,363 Liabilities and stockholders' equity Current portion of operating lease liabilities 1,399 1,384 Long term portion of operating lease liabilities 3,367 3,969 Other current and long-term liabilities 16,645 17,747 Total liabilities 21,411 23,100 Total stockholders' equity $ 260,513 $ 319,263 Expand Astria Therapeutics, Inc. Selected Consolidated Statements of Cash Flows Data (In thousands) (Unaudited) Six Months Ended June 30, 2025 2024 Net cash used in operating activities $ (70,076 ) $ (35,885 ) Net cash provided by (used in) investing activities 86,575 (194,334 ) Net cash provided by financing activities - 141,901 Net increase (decrease) in cash, cash equivalents and restricted cash $ 16,499 $ (88,318 ) Expand

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store